Over the last few decades, IL-11 signalling has been recognised as a key pro-tumourigenic molecule [29,42], with evidence of its importance in the progression of several cancers, including non-small cell lung cancer, pancreatic cancer, renal cell carcinoma, and breast cancer [43,44,45,46]. This evidence concerns the gene IL11 and hereditary clear cell renal cell carcinoma.